Macular Degeneration_Anti-VEGF скачать в хорошем качестве

Macular Degeneration_Anti-VEGF

Macular Degeneration_Anti-VEGF According to the medical record on October 9, 2018, the visual acuity in both eyes had decreased for more than one month. The visual acuity of the right eye was 0.06, the visual acuity of the left eye was 0.1, the cornea of ​​both eyes was bright, the aqueous humor was clear, the anterior chamber was not shallow, and the lens cortex was mixed. A large number of drusen can be seen in the fundus, and choroidal neovascularization can be seen on OCTA examination. The impression of fundus examination is wet macular degeneration. On ultrasound examination, the posterior pole of the right eye was raised, and the vitreous body of both eyes was cloudy. The treatment recommendation is intravitreal injection of anti-VEGF biologics. In the next few days, he changed the outpatient clinic of the second hospital, and then performed binocular cataract surgery in the second hospital. On April 11, 2019, I went to the second home for treatment. The reason for the treatment was still blurred vision in both eyes. The outpatient doctor wrote in the medical record that the doctor recommended anti-VEGF injection therapy, but due to economic reasons, the family members requested conservative treatment. So, instead, the drug prescription, calcium dobesilate capsules. Intravitreal injection of anti-VEGF factor preparations is actually an injection of ranibizumab. The unit price of each dose is 6,000 yuan. The number of injections varies depending on the person's condition. have to be aware of is: 1. The pathological basis of wet macular degeneration is systemic, and anti-VEGF therapy does not target the deep causes of wet macular degeneration. Therefore, once anti-VEGF is stopped, choroidal neovascularization is likely to recur. Therefore, maintaining the efficacy of anti-VEGF therapy is likely to require long-term uninterrupted treatment. 2. The pharmacological properties of ranibizumab and bevacizumab are very similar, but it is only the reason for the registration of the drug manufacturer. ranibizumab is registered as an ophthalmic drug, and bevacizumab is registered as a gastrointestinal tumor drug. But the unit price of ranibizumab is dozens of times that of bevacizumab in the global market. Therefore, there are a large number of reports on the use of bevacizumab in the treatment of wet macular cases. 3. The evaluation of the efficacy of anti-VEGF preparations in the treatment of fundus neovascular diseases is not the result of using the international standard visual acuity chart to measure visual acuity, but the result of using the ETDRS visual acuity chart to measure visual acuity. The range of visual acuity changes reflected by the ETDRS visual acuity chart is often much smaller than that reflected by the international standard visual acuity chart. That is, after the injection of anti-VEGF preparations, even if the changes in vision cannot be measured with the international eye chart, it may be measured with the ETDRS eye chart. That is, when the patient's self-conscious vision has not improved, the use of ETDRS eye chart measurement may show that the vision is still improved. 4. The method of anti-fundus choroidal neovascularization is not limited to injection of anti-VEGF preparations. Other methods include photodynamic therapy and injection hormone therapy. There are few reports on the horizontal comparison of the efficacy of different treatment methods in the industry. 5. Wet macular degeneration, generally speaking, only accounts for one tenth of cases of macular degeneration. Anti-VEGF therapy only targets wet macular degeneration, not other types of macular degeneration.